![SCOTUS Won’t Weigh in on How Whistleblowers Make Valid FCA Claims](https://www.g2intelligence.com/wp-content/uploads/2022/09/Oct22.NLR_.WhistleblowersCasetoSupCt-iStock-1800x1250-1-1080x675.jpg)
SCOTUS Won’t Weigh in on How Whistleblowers Make Valid FCA Claims
The court recently denied the petition to hear a case that would have helped offer clarity on what evidence whistleblowers need to file qui tam lawsuits under the FCA.
The court recently denied the petition to hear a case that would have helped offer clarity on what evidence whistleblowers need to file qui tam lawsuits under the FCA.
A doctor settles alleged FCA violations involving genetic tests, while a clinical lab owner pleads guilty for his role in another scheme.
In this month’s roundup of key lab-related cases, a bizarre twist in the Theranos saga leads to a slim chance of a mistrial.
Most of the recent settlements and enforcement actions involving labs related to medically unnecessary UDTs and genetic tests.
What happens when a compliance officer is the whistleblower in a qui tam retaliation lawsuit?